Patients with familial dysbetalipoproteinemia (FD) associated with the apo E2/2 phenotype exhibit a marked interindividual variability in serum cholesterol and triglyceride concentrations. It has been proposed that this variability is due to a combination of the apo E2/2 phenotype and additional genetic factors implicated in diseases like familial hypercholesterolemia, familial combined hyperlipoproteinemia, and familial hypertrigryceridemia. To further explore the nature of this variability, the lipoprotein profiles of 17 patients with FD associated with the apo E2/2 phenotype were analyzed by a density-gradient ultracentrifugation technique and by 2-16% polyacrylamide gel electrophoresis. It was found that all patients with FD were characterized by 1) markedly increased cholesterol concentrations of large very low density lipoprotein ( 
F amilial dysbetalipoproteinemia (FD), or type HI
hyperlipoproteinemia, is a genetic disorder of lipoprotein metabolism associated with elevations of both serum cholesterol and trigryceride concentrations. 1 -4 Patients with this disorder have an increased risk for the premature development of coronary heart disease and peripheral vascular disease, which may be related to the accumulation of lipoproteins of abnormal composition in the plasma. 5 - 9 The primary genetic defect associated with FD is the occurrence of a variant form of apolipoprotein (apo) E that does not bind normally to either the apo B,E (low density lipoprotein [LDL] ) receptors or to the putative remnant (apo E) lipoprotein receptors, thus leading to an impaired clear-Most patients with FD are homozygous for apo E2 (Arg 158 -»Cys). In Caucasian populations the apo E2/2 phenotype occurs with a frequency of 1%, whereas the frequency of FD is about 1:2,500.
l Thus, FD will develop in only a small percentage of the individuals with the apo E2/2 phenotype. This indicates that in general, FD is a multifactorial disease, i.e., additional factors, either genetic or environmental, are required for its expression. 12 -14 Individuals with FD show a marked interindividual variation in the serum concentrations of cholesterol and triglyceride.
115 - 17 However, the apo E2 (Arg 15 g-»Cys) from hypocholesterolemic, normocholesterolemic, and hypercholesterolemic subjects all showed equally defective binding to the apo B,E (LDL) receptors in vitro. 
BMI, body mass index; Xa, xanthomas; XSP, xanthoma striata palmaris; CAD, coronary artery disease; PVD, peripheral vascular disease; C, cholesterol; TG, triglyceride; VLDL, very low density lipoprotein; apo, apolipoprotein; PT, phenotyping; GT, genotyping; FD, familial dysbetalipoproteinemia; E3-L, E3-Leiden.
'With apo E2(LyS]46-*Gln), as was discovered by allele-specific oligonucleotide probe for the E2(Lys 14 «->Gln) mutation.
ial hypertriglyceridemia, determines the expression of FD. Such a diversity of additional genetic factors would explain both the marked interindividual variability in the cholesterol and triglyceride concentrations in sera of patients with the disorder, as well as the relatively low frequency of the development of FD in individuals with the apo E2/2 phenotype. In addition, this hypothesis predicts that the lipoprotein profiles of patients with FD exhibit characteristic interindividual differences related to the nature of the additional genetic factor (or factors). The aim of the study was to elucidate which combination of lipoprotein abnormalities is associated with the presence of apo E2 (Arg 158 -»Cys) homozygosity and to determine which lipoprotein class (or classes) is responsible for the interindividual variability in the serum cholesterol and triglyceride concentrations in patients with FD.
Methods

Subjects
During routine screening of the apo E phenotype of all patients referred to the Lipid Clinic of the Leiden University Hospital in the period between July 1989 and December 1990, 17 hyperlipoproteinemic individuals with the apo E2/2 phenotype were discovered ( Table 1 ). The sera of these patients were characterized by the presence of )3-very low density lipoprotein (/3-VLDL) as determined by agarose electrophoresis and by elevated VLDL concentration (VLDL cholesterol >1.0 mmol/L) as analyzed by routine ultracentrifugation. The VLDL cholesterol/triglyceride ratio was markedly increased in all patients (Table 1 ). All patients therefore fulfilled the "classic" biochemical criteria for FD. The nature of the apo E2/2 phenotype was analyzed in more detail. Cysteamine treatment 18 of the serum sample before apo E phenotyping led to a "normal" modification of the apo E molecule (e.g., conversion of the apo E2/2 phenotype to the apo E4/4 phenotype). In agreement with this observation it was found that all patients were homozygous for apo E2 (Arg 158 ->Cys) as determined by DNA analysis. 19 It thus appeared that all 17 patients were homozygous for apo E2 (Arg 158 -»Cys), the most common form associated with FD.
Three patients (patients No. 18,19, and 20 in Table 1 ) showed only partial modification with cysteamine during apo E phenotyping. Using both aJlele-specific restriction endonuclease genotyping 19 Table 1 ) was heterozygous for a common APOE3 allele and an APOE3-Leiden allele (7-amino acid insertion in 120-126).
All patients were advised to eat a low-fat diet (30% of total calories) with a saturated: monounsaturated: polyunsaturated fat ratio of 1:1:1 and less than 300 mg cholesterol per day. None of the patients reported a consumption of more than 15 g alcohol per day. None appeared to have renal, thyroid, or liver disease, as assessed by physical examination and routine laboratory tests. One patient (patient No. 1 in Table 1 ) had mild diabetes, but the level of blood glucose was well controlled by diet. All other patients had normal fasting blood glucose levels. None of the patients took lipidlowering drugs or other drugs that might interfere with lipoprotein metabolism.
Ten normolipidemic individuals (six men and four women, average age 47.3 years) served as control subjects in this study. Normolipidemia was defined as a serum cholesterol concentration <6.1 mmol/L and serum triglyceride concentration <2.0 mmol/L. Five of the normolipidemic control subjects had the apo E3/3 phenotype, three the apo E3/2 phenotype, and two the apo E4/3 phenotype.
Density-Gradient Ultracentrifugation
Blood samples were taken in the morning after more than 12 hours of fasting. Serum was obtained by centrifugation at l,000g for 10 minutes at room temperature less than 4 hours after sampling. The separation of lipoproteins was started the day of blood collection using a recently developed two-step density-gradient ultracentrifugation technique (unpublished observations from our laboratory). In the first step high density lipoprotein (HDL), LDL, intermediate density lipoprotein (IDL), and VLDL were separated. In the second step VLDL was further separated into two subtractions, VLDL, (large VLDL) and VLDL 2 (small VLDL). The gradient of the first step consisted of 2 mL serum sample (adjusted to d= 1.210 g/mL by adding solid potassium bromide) on the bottom of a polyallomer tube (14 mL, Kontron AG, Zurich, Switzerland), overlayered by 5 mL of d=1.030 g/mL and 5 mL of d=1.006 g/mL solutions. The gradient was centrifuged immediately at 274,400g for 19 hours at 15°C in a TST swinging-bucket rotor using a Centrikon T-2070 ultracentrifuge (Kontron AG). In the second step the gradient consisted of 2 mL VLDL solution (obtained from routine ultracentrifugation and adjusted to d= 1.210 g/mL by adding solid potassium bromide) on the bottom of the tube, overlayered by 2 mL of d= 1.100 g/mL, 4 mL of d= 1.040 g/mL, and 4 mL of d= 1.006 g/mL solutions. This gradient was ultracentrifuged at 210,000g for 2 hours at 15°C in the same rotor and ultracentrifuge as used in the first step. The gradient was fractionated using a specially designed fractionator 23 connected to a micropump and a fraction collector (LKB, Bromma, Sweden).
Chemical Analysis
The cholesterol concentrations and the compositions of VLDL!, VLDL 2 , IDL, and LDL were determined in pooled gradient fractions. VLDLi was recovered in fractions 21-23 and VLDL 2 in fractions 11-20 in the second-step ultracentrifugation. IDL was obtained in fractions 12-18 and LDL in fractions 6-11 in the first-step ultracentrifugation. The total cholesterol, free cholesterol, triglyceride, and phospholipid concentrations were determined enzymatically using test kits (Boehringer, Mannheim, FRG). Esterified cholesterol was calculated as the difference between total cholesterol and free cholesterol. The mass of cholesteryl ester (CE) was estimated as 1.67 x esterified cholesterol. Total protein was determined by a modification of the Lowry procedure 24 with bovine serum albumin as a standard. The total lipoprotein mass (in milligrams per deciliter) was calculated as the sum of masses of free cholesterol, cholesterol ester, triglyceride, phospholipid, and total protein. HDL cholesterol concentration was measured in the d=1.006 g/mL infranatant obtained by routine ultracentrifugation after precipitation of IDL and LDL by phosphotungstic acid and MgCl 2 .
Gradient Gel Electrophoresis
The lipoprotein profiles in the sera of 20 patients with FD were analyzed by gradient gel electrophoresis. The electrophoresis was performed as described by McNamara et al 25 using 2-16% nondenaturing polyacrylamide gradient gels (Pharmacia LKB, Uppsala, Sweden). The gels were stained with Sudan black B. Stained gels were scanned with an LKB 2202 Ultrascan laser densitometer (LKB, Paramus, N.J.).
Apolipoprotein E Phenotyping and Genotyping
The apo E phenotype was determined by isoelectric focusing of delipidated plasma samples before and after cysteamine treatment followed by immunoblotting as described by Havekes et al. 18 For apo E genotyping, genomic DNA was isolated from leukocytes by standard methods. 26 The 5' part of exon 4 of the human APOE gene, encoding for amino acids 61-174, was amplified by the polymerase chain reaction (PCR) using the primers 402 (nucleotides 3,555-3,574, coding strand) and 401 (nucleotides 3,932-3,913, noncoding strand) as described earlier by van den Maagdenberg et al. 22 For allele-specific restriction endonuclease genotyping as described first by Hixson and Vernier, 19 15 fiL PCR product was digested with 7.5 units restriction enzyme Hha I for 16 hours according to recommendations of the supplier (Pharmacia). Thereafter, the digested material was separated on a 10% neutral polyacrylamide gel for 3 hours at 10 V/cm, stained with 0.1 mg/mL ethidium bromide, and photographed. 20 For hybridization with variant-specific oligonucleotide probes for the APOE2 (Lys^->-Gln) mutation 21 and the APOE3-Leiden mutation, 22 5 fiL PCR product was separated on a 2% agarose gel by electrophoresis, and the gel was stained with ethidium bromide and photographed. Thereafter the DNA was transferred to a membrane (Biotrace, Gelman Sciences Inc., Ann Arbor, Mich.) and hybridized with adenosine 5'-[a-
32 P]triphosphate-labeled synthetic allele-specific oligonucleotide probes. 21 ' 22 
Statistical Analysis
Results were expressed as mean±SD. All statistical analyses were performed with SPSS/PC+ software (SPSS Inc., Chicago, 111.). Differences between mean values were evaluated statistically by Student's t test. Values ofp<0.05 were considered to represent statistical significance.
Results
Characteristics of Subjects
Seventeen patients with FD associated with the apo E2/2 phenotype were studied (Table 1) . They were given detailed dietary instructions. During a 3-12-month follow-up period all patients adhered to these instructions. Three or more measurements of serum cholesterol and triglyceride concentrations (on average, 4.9 measurements) were made per patient during the follow-up period. The mean coefficient of variation for serum cholesterol concentrations in multiple determinations per patient was 10 ±4% and for serum triglyceride concentrations 17±5%, which compared well with corresponding values of 7% (serum cholesterol) and 22% (serum triglyceride) reported for normolipidemic individuals analyzed over a 6-month period.
27 ' 28 This indicates that patients with FD analyzed in the present study did not exhibit an unusual intraindividual variability in their serum cholesterol and triglyceride concentrations, although considerable interindividual differences in these parameters were observed ( Table 1) .
Separation of Lipoproteins
The sera of all the patients with FD and of 10 normolipidemic individuals were analyzed by a densitygradient ultracentrifugation technique and by nondenaturing gradient polyacrylamide (2-16%) gel electropho- Table 1 ) and of a normolipidemic individual analyzed by density-gradient ultracentrifugation are shown in Figure 1 . Four distinct lipoprotein fractions (VLDL,, VLDL 2 , IDL, and LDL) were present in the sera of all patients with FD. A distinct IDL fraction was absent in the sera of normolipidemic individuals. As illustrated in Figure 2 , four distinct lipoprotein fractions were also observed in the sera of all patients with FD analyzed by gradient gel electrophoresis. These lipoprotein fractions corresponded to VLDL,, VLDL 2 , IDL, and LDL fractions isolated by density-gradient ultracentrifugation. Note that a distinct IDL fraction was not detectable in the sera of normolipidemic individuals, as analyzed by densitygradient ultracentrifugation (Figure 1 ) and gradient gel electrophoresis (Figure 2 ).
The average cholesterol concentrations of VLDL,, VLDL 2 , IDL, LDL, and HDL in the sera of 17 patients with FD were compared with those of 10 normolipidemic subjects ( Table 2 ). The cholesterol concentrations of VLDL,, VLDL 2 , and IDL were markedly higher in patients with FD than in normolipidemic subjects, and the LDL cholesterol concentration was considerably lower in FD patients than in normolipidemic individuals. As indicated in Figure 1 , the IDL fraction in a normolipidemic individual contains substantial quantities of particles at the lower end of the LDL spectrum. This suggests that the IDL concentration in normolipidemic individuals is slightly overestimated.
Interindividual Variability of Lipoproteins
An important aspect of this study was the analysis of the interindividual differences in the lipoprotein (sub)-fractions in the sera of patients with FD. In Figure 3 , the cholesterol profiles of three patients with serum cholesterol concentrations of 8.25, 12.29, and 25.25 mmol/L are shown. Only minor interindividual differences in IDL and LDL cholesterol concentrations were observed. As illustrated in Figure 3 , the marked differences in the serum cholesterol concentrations of patients with FD were mainly due to differences in the cholesterol concentrations of VLDL! and VLDL 2 , a phenomenon that was observed in all patients with FD.
The relations between the serum cholesterol concentrations and the cholesterol concentrations of VLDL,, VLDL 2 , IDL, LDL, and HDL in the sera of the 17 patients with FD were analyzed statistically. The cholesterol concentrations of VLDL! ( Figure 4A between the IDL cholesterol concentration and the cholesterol concentration of VLDL 2 (small VLDL) or VLDL, (large VLDL).
FIGURE 4. Scatterplots show relation between the cholesterol concentrations of large very low density lipoprotein (VLDL,) (panel A), small VLDL (VLDL 2) (panel B), intermediate density lipoprotein (IDL) (panel C), and low density lipoprotein (LDL) (panel D) and the serum cholesterol concentration in sera of 17 patients with familial dysbetalipoproteinemia.
The mean composition of lipoproteins isolated from the sera of 17 patients with FD is presented in Table 4 . The VLDL, and the VLDL 2 fractions of patients with FD had a significantly increased CE content and a significantly decreased triglyceride content compared with the VLDL subtractions of normolipidemic individuals. Only minor interindividual differences in the composition of VLDL! and VLDL 2 in the 17 patients with FD were observed. As illustrated in Figure 5 , no correlation between the mass (in milligrams per deciliter) of the VLDL subfractions and the relative contents of CEs or triglycerides was found.
Familial Dysbetalipoproteinemia Associated With Rare Apolipoprotein E Variants
The lipoprotein profiles of three patients with rare apo E variants, two patients with apo E2 (Lys ]<6 -*Gln) and one patient with apo E3-Leiden, were analyzed by density-gradient ultracentrifugation. As illustrated in Figure 6 , major differences in the LDL cholesterol concentrations between patients with FD associated with the apo E2/2 phenotype and patients with rare apo E variants were observed. The patients with apo E2 (Lys 146 ->Gln) (patients No. 18 and 19) had LDL concentrations of 4.32 and 3.70 mmol/L, and the patient with apo E3-Leiden (patient No. 20) had an LDL cholesterol concentration of 2.59 mmol/L. In these patients we could not adequately separate LDL and IDL by the density-gradient ultracentrifugation technique ( Figure 6 ). The concentration and composition of the VLDL subfractions between the patients with FD associated with the apo E2/2 phenotype and the patients with the rare apo E variants did not differ markedly.
Discussion
In the present study the lipoprotein profiles of 17 patients with FD associated with the apo E2/2 phenotype were analyzed in detail. The relative contribution of the different lipoprotein (sub)classes to the marked interindividual variability in the concentrations of lipids in the sera of patients with FD was evaluated. This evaluation might contribute to a better understanding of the factors that influence the development of hyperlipoproteinemia associated with the apo E2/2 phenotype. Since several reports suggest that the expression of FD in individual patients is dependent on factors such as diet, alcohol consumption, body weight, and endocrinological disturbances, 1 -3 considerable efforts were made to minimize the effects of these factors in the patient population studied in this report. During a 3-12-month follow-up period the serum lipid and lipoprotein concentrations remained quite constant. However, considerable interindividual differences as to the serum lipid levels were noted (Table 1) , with cholesterol concentrations ranging from 7 to 25 mmol/L and triglyceride concentrations ranging from 3 to 28 mmol/L.
In agreement with observations published earlier, 1315 - 29 it was found that all patients with FD were characterized by markedly increased IDL concentrations compared with normolipidemic individuals (Table  2) . However, the IDL cholesterol concentration in the patients with FD was not correlated to the serum cholesterol and triglyceride concentrations. Moreover, the IDL concentration in FD patients showed only minor interindividual variability.
Several studies have provided evidence that, on average, the LDL cholesterol concentration in patients with FD is not increased compared with the LDL cholesterol concentration in normolipidemic individuals. '-3 However, a rather large interindividual variability of the LDL cholesterol concentration in patients with FD has been observed.
-
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- 31 Indeed, in some patients with FD, markedly increased serum LDL concentrations were reported, 17 suggesting that the apo E2/2 phenotype was superimposed by familial hypercholesterolemia or familial combined hyperlipoproteinemia. However, in the present study no significant interindividual variability of the LDL cholesterol concentration was found, and none of the patients had a distinctly elevated LDL cholesterol concentration (Table 2 ). It should be noted that in the present study, LDL was isolated by density-gradient ultracentrifugation and not by sequential ultracentrifugation. In preliminary studies we found that approximately 70% of the IDL isolated by density-gradient ultracentrifugation was recovered in the density interval of 1.006-1.019 g/mL when subjected to sequential ultracentrifugation, and the remaining 30% was recovered in the ^=1.019-1.063 g/mL fraction. Thus, if the LDL of patients with FD is isolated by sequential ultracentrifugation, the concentration of LDL is overestimated. Serum VLDL from patients with FD and from normolipidemic individuals was separated into two subtractions (VLDLj and VLDL 2 ). In comparison to the VLDL subfractions from normolipidemic individuals, the VLDL subfractions from FD patients were enriched in CEs (Table 4) . Interestingly, the chemical composition of VLDL, and VLDL 2 was not related to their concentrations in serum ( Figure 5 ).
As shown in Figure 4 the differences in the cholesterol concentrations of VLDLj and VLDL 2 were mainly responsible for the observed interindividual variability in the concentration of cholesterol in the sera of FD patients. This suggests that the additional (genetic) factors that have been considered to be required for the expression of this disorder in individuals with the apo E2/2 phenotype 113 play a role in the regulation of VLDL concentration. This hypothesis is supported by data from an extensive family study of patients with FD reported by Stuyt et al. 32 They observed that many family members were characteri2ed by a mild-to-moderate increase in the plasma trigtyceride concentration, whereas only a few family members had an increased plasma cholesterol concentration. 32 A similar occurrence of hypertriglyceridemia in family members of patients with FD was noted by Hazzard et al. 14 These observations suggest that a combination of the apo E2/2 phenotype and a genetic abnormality in the metabolism of the triglyceride-rich lipoproteins is required for the expression of FD. It is possible that several different genetic abnormalities in the metabolism of the triglyceride-rich lipoproteins have the capacity to generate the expression of FD in individuals with the apo E2/2 phenotype. The variability in the expression of FD could therefore be due to differences in the effects of specific genetic abnormalities in the metabolism of the triglyceride-rich lipoproteins in individuals with the apo E2/2 phenotype.
Despite marked interindividual differences in the concentration of lipids and lipoproteins in the sera of FD patients, several features in the lipoprotein profiles were consistently observed in all patients: a depressed LDL cholesterol concentration, a markedly elevated IDL cholesterol concentration, and an altered composition (enrichment by CE) of both VLDL, and VLDL 2 .
In an extensive analysis of normolipidemic individuals and of a large number of patients with various types of primary and secondary hyperlipoproteinemias, we have not found a single individual with this combination of abnormalities, except for FD patients. Thus, it appears that the combined presence of a low LDL cholesterol concentration, a high EDL cholesterol concentration, and an altered VLDL composition is a unique feature of FD patients with the apo E2/2 phenotype. In preliminary studies we found that the lipoprotein profiles of individuals with the apo E2/2 phenotype and serum cholesterol levels below 7.0 mmol/L were characterized by the same combination of abnormalities. This indicates that both normolipidemic and hyperlipidemic individuals with the apo E2/2 phenotype are character- ized by a similar combination of lipoprotein abnormalities, suggesting that apo E2/2 is a primary factor in the pathophysiology of these abnormalities. Since experimental studies indicate that apo E2 (Arg 158 ->Cys) has a defective interaction with the apo B,E (LDL) receptor, 10 it is tempting to speculate that impaired receptor binding in individuals with the apo E (Arg 158 -*Cys) homozygosity is responsible for the observed combination of lipoprotein abnormalities. In an attempt to explore this hypothesis the lipoprotein profiles of patients with rare apo E mutants, one patient with apo E3-Leiden and two patients with apo E2 (Lys 146 -*Gln), were analyzed ( Figure 6 ). In the patients with apo E2 (LySi«,->Gln), the LDL cholesterol concentration was higher and the IDL cholesterol concentration lower than in the patients with the apo E2/2 phenotype. In the patient with apo E3-Leiden, the cholesterol concentrations of LDL and IDL were intermediate between those in patients with the apo E2/2 phenotype and in patients with apo E2 (Lys 146 -»Gln).
Since it was demonstrated that the LDL receptor binding activities of apo E2 (Arg 158 -»Cys), E3-Leiden, and E2 (Lys^^Gln) were 1%, 25%, and 40%, respectively, of the binding of apo E3, 10 these observations suggest that the apo B,E (LDL) receptor binding activity of apo E is related to the concentrations of LDL and IDL. More detailed studies are required to test the hypothesis that the apo B,E (LDL) receptor binding activity of apo E is directly linked to the regulation of the concentrations of LDL and IDL in plasma.
